Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
  • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
  • C07J71/0036—Nitrogen-containing hetero ring
  • C07J71/0042—Nitrogen only
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Definitions

• the invention relates to biologically active vitamin D compounds. More specifically, this invention relates to 1 ⁇ -hydroxyvitamin D 2 analogs which exhibit unexpected biological properties. Background
• vitamin D derivatives specifically, 1 ⁇ ,25-dihydroxyvita min D 3 and 1 ⁇ -hydroxyvitamin D 3
• certain vitamin D derivatives also affect cellular differentiation processes and are capable of inhibiting the growth and proliferation of certain leukemic cells [Suda et al., U.S. Patent 4,391,802; Suda et al. Proc. Natl. Acad. USA 80, 201 (1983) ; Reitsma et al., Nature, 306, 492-494 (1983)] .
• vitamin D metabolites and analogs are derivatives of the vitamin D 3 series, i.e. they possess saturated steroid side chains.
• Side chain unsaturated vitamin D compounds are, however, also known, namely certain hydroxyderivatives of vitamin D 2 such as 25-hydroxyvitamin D 2 (U.S. Patent 3,585,221), 1 ⁇ ,25-dihydroxyvitamin D 2 (U.S. Patent 3,880,894), the 24-hydroxy- and 24,25-dihydroxyvitamin D 2 metabolites (Jones et al., Arch. Biocherru Bicphys. 202, 450 (1980)), 1 ⁇ -hydroxyvitamin D 2 (U.S.
• Patent 3,907,843 discloses certain related 22-trans-dehydro compounds lacking the 24-methyl substituent as described in U.S. Patent 3,786,062 and by Bogoslovskii et al. (J. Gen. Chem. USSR 48 (4) , 828 (1978); Chem. Abstr. 89, 163848j, 89, 209016s). Disclosure of Invention
• R is hydrogen or a hydroxy group.
• the compound of this invention wherein R is hydrogen can be obtained as an intermediate in the preparation of the compound where R is hydroxy.
• the compounds of this invention are analogs of hydroxyvitamin D 2 compounds which lack the 24-methyl substituent, i.e. the c ⁇ rpounds are 1 ⁇ -hydroxy-28-norvitamin D 2 and 1 ⁇ ,25-dihydroxy-28-norvitamin D 2 , respectively.
• the starting material is the diene-protected aldehyde of structure (1) (see Process Scheme I) , which is prepared from ergosterol acetate according to the method of Barton et al. (J. Chem. Soc. (C) 1968 (1971) ) . Reaction of aldehyde (1) with 3-methyl-1-butylphenylsulfone having the structure shown below:
• a small amount of the corressponding 1 ⁇ -hydroxy epimer may also be present in the product, but separation of the epimers, though possible by chromatography is not necessary at this stage.
• Heating of this 1-hydroxycyclovitamin D intermediate in glacial acetic acid at 40-60°C then provides a mixture of the 3-acetylated solvolysis products from which are isolated by chromatography the 5,6-cis and 5,6-trans compounds of structures (8) and (9) , respectively. If the 1-hydroxycyclovitamin D product subjected to soivolysis contained some 1 ⁇ -hydroxy-epimer, then the soivolysis mixture will contain also the 1 ⁇ -hydroxy epimers corresponding to compounds (8) or (9) and, if desired, these can also be isolated by chromatography.
• This diol (10) is then subjected to in vitro enzymatic hydroxylation at carbon 25, using a liver homogenate prepared from vitamin D-deficient rats, (as described in United States Letters Patent No. 4,307,025) to obtain, after chromatographic separation of the product mixture, the desired 1 ⁇ ,25-dihydroxylated product, represented by structure (12) , in pure form.
• structure (12) in pure form.
• High pressure liquid chromatography was performed on a Waters Associates Model ALC/GPC 204 using a Zorbax-Sil (Dupont) column (6.2 mm x 25 cm column, flow rate 4 ml/min, 1500 psi).
• Column chromatography was performed on Silica Gel 60, 70-230 mesh ASTM (Merck) .
• Preparative thin-layer chromatography was carried out on Silica 60 PF-254 (20 x 20 cm plates, 1 mm silica gel). Irradiations were carried out using a Hanovia 608A36 mercury arc lamp fitted with a Vycor filter. All reactions are preferably performed under an inert atmosphere (e.g. argon).
• the organic extract was washed with saturated NaHCO 3 , saturated copper sulfate and water, dried (Na 2 SO 4 ) and concentrated in vacuo to obtain the oily 3 ⁇ -tosyl derivative.
• the crude tosylate was treated with NaHCO 3 (150 mg) in anhydrous methanol (10 ml) and the mixture was stirred for 8.5 h at 55°C. After cooling and concentration to ⁇ 2 ml the mixture was diluted with benzene (80 ml) , washed with water, dried (Na 2 SO 4 ) and evaporated under reduced pressure.
• the resulting oily 3,5-cyclovitamin D analog (6) was sufficiently pure to be used for the following oxidation step without any purification.
• the above product comprised chiefly the 1 ⁇ -hydroxycyclovitamin D analog of structure (7) and a small amount of the corresponding 1 ⁇ -epimer.
• a solution of this 1-hydroxyclovitemin D product (12 mg) in glacial acetic acid (0.5 ml) was heated at 55°C for 15 min. The mixture was carefully poured into ice/saturated NaHCO 3 and extracted with benzene and ether. The combined extracts were washed with water, dried (Na 2 SO 4 ) and evaporated.
• Incubation was carried out in 10 ml incubation medium in a 125 ml Erlenmayer flask containing an aliquot of liver homogenate representing 1 g of tissue, 0.125 M sucrose, 50 mM phosphate buffer (pH 7.4) , 22.4 mM glucose-6-phosphate, 20 m ATP, 160 mM nicotinamide, 25 mM succinate, 0.4 mM NADP, 5 mM MgCl 2 , 0.1 M KCl and 0.5 units glucose-6-phosphatedehydrogenase.
• the reaction was initiated by addition of 400 ⁇ g of compound (10) dissolved in 100 ⁇ l 95% ethanol.
• the mixture was incubated at 37°C with shaking at 80 oscillations/min for 3 h.
• the reaction was stopped by the addition of 20 ml methanol and 10 ml dichlorcmethane. After further addition of 10 ml dichloromethane, the organic phase was collected while aqueous phase was re-extracted with 10 ml dichloro methane.
• the organic phases from total of three extractions were combined and evaporated with a rotary evaporator.
• the residue containing the desired product was dissolved in 1 ml of CHCl 3 :Hexane (65:35) mixture and applied to a Sephadex LH-20 column (0.7 cm x 14 cm) packed, equilibrated and eluted with the same solvent.
• the product was further purified by high performance liquid chrcmatograpl ⁇ y using a reverse phase column (Richrosorb Rp-18, 4.6 mm x 25 cm, E. Msrck, Darmstadt, West Germany) operated under pressure of 1200 psi and a flow rate of 2 ml/min.
• the column was eluted with 22% H 2 O in methanol and the product was eluted at 50 ml.
• the product was further purified by HPLC using Zorbax-Sil and conditions as described above.
• the resulting product was characterized by the following data: UV absorption (95% ethanol) ⁇ max 265 nm, ⁇ min 228 nm; mass spectrum, m/z 414 (mol.
• the compounds of this invention can be readily obtained in crystalline form by crystallization from suitable solvents, e.g. hexane, ethers, alcohols, or mixtures thereof, as will be apparent to those skilled in the artt Biological Activity of Side Chain I-ehydrovitamin D Compmunds.
• suitable solvents e.g. hexane, ethers, alcohols, or mixtures thereof, as will be apparent to those skilled in the artt Biological Activity of Side Chain I-ehydrovitamin D Compmunds.
• Rats were then divided into groups of 6 rats each and were given 650 pmol of either compound (10) or 1 ⁇ -hydroxyvitamin D 3 (1 ⁇ -OH-D 3 ) dissolved in 0.05 ml 95% ethanol intrajugularly 18 h prior to sacrifice.
• the rats in the control group were given ethanol vehicle in the same manner.
• the rats were killed by decapitation and the blood was collected. Serum obtained by centrifugation of the blood was diluted with 0.1% lanthanum chloride solution (1:20) and serum calcium concentration was measured with an atomic absorption spectrophot ⁇ eter. Results are shown in the Table I below:
• Rats in a control group received 0.05 ml 95% ethanol intrajugularly while rats in the test groups were given 325 pmol of either compound (12) or of 1 ⁇ ,25-dihydroxyvitamin D 3 (1 ⁇ ,25-(OH) 2 D 3 ) dissolved in
• Day-old white Leghorn male chicks were obtained from Northern Hatcheries (Beaver Dam, WI) . They were fed the vitamin D-deficient soy protein diet described in Cirdahl et al (Biocherrdstry 10, 2935-2940, 1971) for 3 weeks at which time they were vitamin D deficient. They were then divided into groups of 6 chicles each. One group received Wesson oil vehicle by mouth; the other groups received the indicated c-cmp ⁇ unds (see Table III) dissolved in the same amount of Wesson oil each day for 7 days. Twenty-four hours after the last dose, all chicks were killed by cervical dislocation.
• compound (12) which is the 24-desmethyl analog of the known 1 ⁇ ,25-dihydroxyvitamin D 3 , should function to provide bone mineralization in chicks equivalent to that shown by 1 ⁇ ,25-dihydroxyvitamin D 3 ; thus this novel vitemin D 2 analog would be fully active in the chick.
• the compounds of this invention will find ready application as substitutes for various of the known vitamin D metabolites in the therapy or prophylaxis of calcium metabolism disorders such as rickets, hypoparathyroidism, osteodystrophy, ostecmalacia or osteoporosis in the human, or related calcium deficiency diseases (e.g. milk fever) in animals.
• these compounds may be used for the treatment of certain malignancies, such as human leukemia.
• these compounds would have particular utility in the prevention or treatment of calcium imbalance-induced conditions (e.g. egg shell thinness, poultry leg weakness) in poultry where all the known vitamin D 2 derivatives exhibit very poor activity.
• the compounds may be administered by any conventional route of administration and in any form suitable for the method of administration selected.
• the compounds may be formulated with any acceptable and innocuous pharmaceutical carrier, in the form of pills, tablets, gelatin capsules, or suppositories, or as solutions, emulsions, dispersions or suspensions in innocuous solvents or oils, and such formulation may contain also other therapeutically active and beneficial ingredients as may be appropriate for the specific applications.
• the compounds are advantageously adrrdissered in amounts frcm 0.5 to 10 ⁇ g per day, the specific dosage being adjusted in accordance with the specific ccmpound administered, the disease treated and the condition and response of the subject, as is well understood by those skilled in the art.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Obesity (AREA)
• Diabetes (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Nutrition Science (AREA)
• Endocrinology (AREA)
• Rheumatology (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (1)

Family

ID=24344548

Family Applications (1)

Country Status (12)

Cited By (4)

Citations (4)

Family Cites Families (4)

• 1985
  • 1985-01-22 AU AU38895/85A patent/AU584071B2/en not_active Ceased
  • 1985-01-22 JP JP60500734A patent/JPH064536B2/ja not_active Expired - Lifetime
  • 1985-01-22 WO PCT/US1985/000097 patent/WO1985003939A1/en active Application Filing
  • 1985-01-22 DE DE19853590080 patent/DE3590080T/de active Pending
  • 1985-01-22 NL NL8520021A patent/NL8520021A/nl unknown
  • 1985-01-22 DE DE3590080A patent/DE3590080C2/de not_active Expired - Lifetime
  • 1985-01-22 CH CH4779/85A patent/CH667658A5/de not_active IP Right Cessation
  • 1985-01-25 IL IL74168A patent/IL74168A/xx not_active IP Right Cessation
  • 1985-03-01 IE IE520/85A patent/IE57951B1/en not_active IP Right Cessation
  • 1985-03-04 FR FR8503135A patent/FR2560597B1/fr not_active Expired
  • 1985-03-04 GB GB08505486A patent/GB2155478B/en not_active Expired
  • 1985-03-05 BE BE0/214606A patent/BE901879A/fr not_active IP Right Cessation
  • 1985-11-04 DK DK506985A patent/DK153145C/da not_active IP Right Cessation

Patent Citations (4)

Also Published As

Similar Documents

Legal Events